Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us

COVID-19 updates

Picture

COVID-19 Update #75 for 3/30/2021

3/30/2021

 
COVID-19 Vaccines
 
In a retrospective review of 39,156 asymptomatic patients, in the Mayo Clinic Health System, who were tested for COVID-19 for an upcoming procedure, 1.4% of vaccinated patients tested positive compared to 3.2% of unvaccinated patients for an 80% reduction in the development of asymptomatic COVID-19 with the vaccine.
 
CDC researchers analyzed results of COVID-19 tests from 3,950 health care workers and first responders to estimate real-world effectiveness of the COVID-19 mRNA vaccines. Vaccine effectiveness was found to be 80% after one immunization and 90% in fully vaccinated individuals.
 
COVID-19 Antibodies
 
Lilly, Vir and GSK announced that in the seven-day, Phase II, BLAZE-4 trial (NCT04634409), treatment with bamlanivimab plus VIR-7831 reduced viral load compared to placebo in low-risk adult patients with mild to moderate COVID-19.
 
COVID-19 Anti-Inflammatories
 
Humanigen announced that in a 28-day, 520 patient, Phase III trial (NCT04351152), 15.6% of patients treated with lenzilumab died or required a ventilator compared to 22.1% with placebo in hospitalized hypoxic COVID-19 patients not requiring invasive mechanical ventilation. In the trial, 88% of patients received a corticosteroid, 62% received remdesivir, and 57% received both.
 
Fluvoxamine, a selective serotonin reuptake inhibitor and sigma-1 receptor (S1R) agonist, approved for the treatment of obsessive-compulsive disorder, is being evaluated for the treatment of COVID-19. Inhibiting S1R decreases cytokine production through its interaction with the endoplasmic reticulum stress sensor inositol-requiring enzyme 1alpha (IRE1). The decrease in cytokines reduces the inflammatory response, which diminishes progression of COVID-19.
  • In a 15-day, 152 patient, Phase II trial (NCT04342663), no patient treated with fluvoxamine experienced clinical deterioration (shortness of breath or oxygen saturation of 92% or less) compared to 8.7% with placebo in nonhospitalized patients with severe acute respiratory syndrome from COVID-19. Patients were mostly white and over half were female with a median age of 45 to 46.
  • In a 14-day, 113 patient, non-randomized, Phase III trial (NCT04668950), no patient treated with fluvoxamine required hospitalization compared to 12.5% of observation patients with COVID-19. At day 14, no fluvoxamine patient continued to have symptoms compared to 60% of observation patients. The patient population was mostly male Latinos with a median age of 42 recruited from an occupational setting with congregate living at a horse racing track in California. Fewer patients that chose to receive fluvoxamine were asymptomatic (38% vs 58%) at the beginning of the study.

Comments are closed.
    Stay informed, subscribe to the Prescribe Right Pharmaceutical Pipeline Tracker

    Archives

    January 2023
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020

    Categories

    All

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.